GFRA3 (Nadecnemab Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA009381MB1HU
Size US$199
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
REGN5069 research-grade biosimilar; REGN 5069 research-grade biosimilar; REGN-5069 research-grade biosimilar; GFRA3 antibody; UNQ339/PRO538/PRO3664 antibody;GDNF family receptor alpha-3 antibody; GDNF receptor alpha-3 antibody; GDNFR-alpha-3 antibody; GFR-alpha-3 antibody
Species Reactivity
Human
Immunogen
Recombinant Human GFRA3 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for the glial cell line-derived neurotrophic factor, ARTN (artemin). Mediates the artemin-induced autophosphorylation and activation of the RET receptor tyrosine kinase.
Gene References into Functions
  1. increased GFRalpha3 expression is significantly correlated with poor prognosis of patients with urothelial carcinoma PMID: 28651425
  2. Mir-34a directly regulates GFRA3 via its coding region.GFRA3 is crucial for breast cancer growth. PMID: 28356515
  3. The GFRA3 promoter region showed marked hypermethylation in almost all tumors, and its correlation with survival and other clinicopathological parameters may have important prognostic significance. PMID: 26984265
  4. The lack of expression of the RET/GFRA system could be related to the cell mislocation and deregulated growth of craniopharyngiomas. PMID: 22031517
  5. Artemin and GFRalpha3 expressions may play an important role in perineural invasion of pancreatic carcinoma. PMID: 19304517
  6. 1.92 A crystal structure of the complex formed between ARTN and its receptor GFRalpha3 was reported. PMID: 16765900
  7. In the human digestive and reproductive systems, a subset of epithelial cells exhibited GFRalpha3- and RET-like staining, suggesting co-localization. PMID: 16773224

Show More

Hide All

Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor.
Protein Families
GDNFR family
Tissue Specificity
Widely expressed in adult and fetus which exhibit a similar pattern. Essentially not expressed in the central nervous system, but highly expressed in several sensory and sympathetic ganglia of the peripheral nervous system. Moderate expression in many non
Database Links

HGNC: 4245

OMIM: 605710

KEGG: hsa:2676

STRING: 9606.ENSP00000274721

UniGene: Hs.58042

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*